Except for inhibiting tumor cell viability directly, EGFR-TKIs could also enhance the immune function of T cells by downregulating the expression of PD-L1 and enhancing the production of interferon-γ (an indicator of T-cell function) as revealed in a cell study (15). The gene discussed is EGFR; the disease is neoplasm.